Project Description

About Medicure

Medicure is a pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics for the U.S. market

Medicure’s vision is to become a leading cardiovascular pharmaceutical company within the U.S, offering a growing product portfolio of cardiovascular products that improve patients’ lives. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients, healthcare providers and shareholders. Our commitment to service, partnership and integrity is what sets us apart.

Medicure was established in 1997, and spent its first decade focused on research and development. In 2008, the company began a transition to focus on its commercial pharmaceutical business. This new direction has provided significant shareholder value with the growth of Aggrastat® (tirofiban hydrochloride) sales, achieving profitability, and the pursuit of development and acquisition opportunities.

Medicure

Amount: $60.0 Million

Type: Senior Secured Term Loan

Purpose:  Acquisition Financing

Head Office:  Winnipeg, Manitoba

Ownership:  Public

Date:  November 2016

Subscribe to our newsletter to get the latest news and insights right in your inbox.

Subscribe
© 2020 Crown Capital Partners Inc.
Terms of UsePrivacy Policy